These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26830473)

  • 1. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.
    Alghamdi S; Khan I; Beeravolu N; McKee C; Thibodeau B; Wilson G; Chaudhry GR
    Stem Cell Res Ther; 2016 Feb; 7():22. PubMed ID: 26830473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
    Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
    Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells.
    Bakshi S; McKee C; Walker K; Brown C; Chaudhry GR
    Oncotarget; 2018 Sep; 9(73):33853-33864. PubMed ID: 30333915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
    Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
    Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
    Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
    Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.
    Wang L; Wu X; Wang R; Yang C; Li Z; Wang C; Zhang F; Yang P
    Biol Res; 2017 May; 50(1):19. PubMed ID: 28545522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
    Liu X; Wu H; Huang P; Zhang F
    J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
    Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
    Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
    Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
    Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.
    Batsali AK; Pontikoglou C; Koutroulakis D; Pavlaki KI; Damianaki A; Mavroudi I; Alpantaki K; Kouvidi E; Kontakis G; Papadaki HA
    Stem Cell Res Ther; 2017 Apr; 8(1):102. PubMed ID: 28446235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JQ1: a novel potential therapeutic target.
    Shi X; Liu C; Liu B; Chen J; Wu X; Gong W
    Pharmazie; 2018 Sep; 73(9):491-493. PubMed ID: 30223929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JQ1, a selective inhibitor of BRD4, suppresses retinoblastoma cell growth by inducing cell cycle arrest and apoptosis.
    Zhang Y; Duan S; Jang A; Mao L; Liu X; Huang G
    Exp Eye Res; 2021 Jan; 202():108304. PubMed ID: 33080301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
    Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
    Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
    Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.